Comparative Pharmacology
Head-to-head clinical analysis: IMITREX versus ZECUITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMITREX versus ZECUITY.
IMITREX vs ZECUITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial blood vessels and inhibits release of pro-inflammatory neuropeptides.
Selegiline is a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B). It inhibits the breakdown of dopamine by MAO-B, increasing dopaminergic activity in the brain.
50 mg to 100 mg orally at onset of migraine; may repeat after 2 hours if needed, max 200 mg/day. Alternatively, 6 mg subcutaneously once, may repeat after 1 hour, max 12 mg/day. Intranasal: 5 mg to 20 mg in one nostril at onset; may repeat after 2 hours, max 40 mg/day.
Apply one 1.3 mg/24 hour transdermal system to a clean, dry, hairless area of the upper arm or thigh for 24 hours; can be repeated at 24-hour intervals for up to 12 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours (range 2–3 hours). This short half-life supports its use for acute migraine attacks but may require repeat dosing for prolonged symptoms.
The terminal elimination half-life of sumatriptan is approximately 2 hours (range 1–4 hours). Due to this short half-life, a second dose may be considered if migraine recurs after initial relief, but no more than two doses in 24 hours via the same route.
Primarily renal excretion of unchanged drug and metabolites (approximately 80% of total clearance), with about 20% eliminated in feces via biliary excretion. About 40% of the dose is excreted unchanged in urine.
Sumatriptan is primarily eliminated by metabolism followed by renal excretion of metabolites. Approximately 60% of a dose is recovered in urine (22% as unchanged sumatriptan, 38% as metabolites) and 40% in feces (primarily metabolites).
Category C
Category C
Triptan
Triptan